Cardiology Online - International Academy of Cardiology
»search site
The International Academy of Cardiology is dedicated to the advancement of global research in cardiovascular medicine through the support of scientific meetings and publications.
   Home Page
   Discussion Groups
   Job Opportunities
   Contact Us





18th World Congress on Heart Disease



Elizabeth Barrett-Connor, M.D., UCSD Dept. of Family and Preventive Medicine, La Jolla, CA, USA


Given the consistent inverse association of HDL cholesterol (HDL-C) with cardiovascular disease (CVD), there is immense interest in developing therapies that raise HDL-C. But HDL-C, the cholesterol carried by HDL particles, may not fully capture HDL-related cardioprotection. HDL-C is carried within HDL lipoprotein particles that are heterogeneous in size, density, charge, core lipid composition, specific apolipoproteins, and function. Recent failures of drugs targeting HDL-C have fueled interest in other metrics of HDL, including HDL particle number (HDL-P), size, and function. We hypothesized that HDL-C cardioprotection may at least partly be influenced by metabolic correlations with other lipoproteins, particularly atherogenic particles, but that HDL-P may be less affected. Using data from 5,598 individuals (ages 45-84 years) from the prospective Multi-Ethnic Study of Atherosclerosis (MESA), we compared the association of chemically-assayed HDL-C and NMR-spectroscopy-measured HDL-P with subclinical atherosclerosis and incident CVD before and after accounting for atherogenic particles. HDL-C was correlated with HDL-P (r = 0.73). Notably, HDL-C associations with atherosclerosis and incident CVD were substantially attenuated and became non-significant after adjusting for atherogenic lipoproteins. In contrast, HDL-P associations with atherosclerosis and incident events were relatively unaffected. In addition, a very high HDL-C also conferred increased risk (HR 2.59, 95% CI 1.11-6.02) after adjusting for HDL-P, while very high HDL-P remained inversely related to risk (HR 0.50, 95% CI 0.19-1.35). These results may have implications both for risk assessment and evaluating therapeutic interventions, particularly pharmacologic interventions which may differentially affect several lipid and lipoprotein parameters concurrently.




©1998-2014 Cardiology Online, Inc. All rights reserved.
Cardiology Online is a registered trademark of Cardiology Online, Inc.